| Chemical Properties | Back Directory | [Boiling point ]
470.0±14.0 °C(Predicted) | [density ]
1.574±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: < 1 mg/mL (insoluble or slightly soluble) *NSC745885 is usually formulated as a suspension. | [form ]
Solid | [pka]
-1.90±0.20(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers[1][2]. | [in vivo]
NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin[1]. | Animal Model: | Eight-week-old NOD/SCID (NOD.CB17 Prkdcscid/J) mice[1] | | Dosage: | 2 mg/kg | | Administration: | Intraperitoneal injection; 2 mg/kg; once daily; 10 days | | Result: | Inhibited engrafted tumors growth in vivo. |
| [IC 50]
EZH2 | [References]
[1] Chen YW, et al.A novel compound NSC745885 exerts an anti-tumor effect on tongue cancer SAS cells in vitro and in vivo.PLoS One.?2014 Aug 15;9(8):e104703. DOI:10.1371/journal.pone.0104703
[2] Tang SH, et al. Pharmacologic?down-regulation?of?EZH2?suppresses?bladder?cancer?in?vitro?and in?vivo.Oncotarget.?2014 Nov 15;5(21):10342-55. DOI:10.18632/oncotarget.1867 |
|
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|